Report overview
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine. This report contains market size and forecasts of Peptide Cancer Vaccine in global, including the following market information:
Global Peptide Cancer Vaccine Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Peptide Cancer Vaccine Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Peptide Cancer Vaccine companies in 2022 (%)
The global Peptide Cancer Vaccine market was valued at US$ 562.7 million in 2022 and is projected to reach US$ 1895.9 million by 2029, at a CAGR of 18.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
We surveyed the Peptide Cancer Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Peptide Cancer Vaccine Market, by Pipeline, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Peptide Cancer Vaccine Market Segment Percentages, by Pipeline, 2022 (%)
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Global Peptide Cancer Vaccine Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Peptide Cancer Vaccine Market Segment Percentages, by Application, 2022 (%)
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Global Peptide Cancer Vaccine Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Peptide Cancer Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Peptide Cancer Vaccine revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Peptide Cancer Vaccine revenues share in global market, 2022 (%)
Key companies Peptide Cancer Vaccine sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Peptide Cancer Vaccine sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Outline of Major Chapters:
Chapter 1: Introduces the definition of Peptide Cancer Vaccine, market overview.
Chapter 2: Global Peptide Cancer Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Peptide Cancer Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
